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Abstract
Heterogeneity is a hallmark of all cancers. Tumor heterogeneity is found at
different levels – interpatient, intrapatient, and intratumor heterogeneity.
All of them pose challenges for clinical treatments. The latter two sce-
narios can also increase the risk of developing drug resistance. Although
the existence of tumor heterogeneity has been known for two centuries, a
clear understanding of its origin is still elusive, especially at the level of
intratumor heterogeneity (ITH). The coexistence of different subpopula-
tions within a single tumor has been shown to play crucial roles during
all stages of carcinogenesis. Here, using concepts from evolutionary game
theory and public goods game, often invoked in the context of the tragedy
of commons, we explore how the interactions among subclone populations
influence the establishment of ITH. By using an evolutionary model, which
unifies several experimental results in distinct cancer types, we develop
quantitative theoretical models for explaining data from in vitro exper-
iments involving pancreatic cancer as well as vivo data in glioblastoma
multiforme. Such physical and mathematical models complement exper-
imental studies, and could optimistically also provide new ideas for the
design of efficacious therapies for cancer patients.
Keywords: Cancer; complexity; heterogeneity; cooperation; public goods; un-
equal allocation.
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1 Introduction
Cancer is frequently described as a genetic disease arising through clonal evo-
lution of cells. It is well appreciated that cancer is not just one but a group of
diseases. Based on the original cell types and organs, cancer has been classified
into more than one hundred different types[1]. From the latest statistics in the
United States (see Table1), it is estimated that there are more than 1.5 million
people are diagnosed as cancer patients, and over one third of them would die
in 2019[2]. Cancer is the second leading cause of death worldwide, and it also
leads to the highest economic loss, which is estimated at approximately $1.16
trillion in 2010[3, 4]. Therefore, cancer has become not only a major public
health issue but also imposes a great economic burden on the society.
However, we still do not have any effective cure or even the ability to control
most cancer types, although significant breakthroughs have been achieved in
the past few decades for cancer prevention, understanding and even treatment
in certain cases[1, 5]. The difficulty in the war against cancer is due to the com-
plexity of this fatal disease, which exists in many different forms. Furthermore,
the highly variable evolutionary properties also makes it extremely difficult to
treat[1, 6]. In addition, cancer is a massively heterogeneous disease at several
different levels[7, 8]. Even within the same tumor, it can contain many different
subpopulations with either genetic or epigenetic variations[9]. Another aspect
which makes the disease even more difficult to study is that cancer cells are not
independent moieties but rather should be viewed as an evolving ecosystem[10].
Each cancer cell competes with others for limited resources and space subject
to Darwinian evolution[6, 11]. Also it is frequently found that different cancer
cell subpopulations cooperate with each other to overcome many biological con-
straints during their development[10]. Therefore, we might need new methods
and models to understand the complexity of cancer at single cell level (µm size)
to tumor (several milli meters), and finally at the scale of an individual (meters).
In this article, we first briefly review the complexity of cancer and discuss
some progress in modeling cancer progression with particular emphasis on intra-
tumor heterogeneity (ITH). Then, illustrate the use of the mathematical model
to explain the phenomena of ITH observed in vitro experiments on pancreatic
cancer and an in vivo study on glioblastoma multiforme (GBM). The theoretical
study also provides some potential insights into cancer treatment methods.
2 Complexity of Cancer
2.1 Cancer types
A recent compilation shows that there are about forty types of cancer based on
the site of origin, such as lung, kidney, colon cancers and so on (see Table 1)[2].
Due to the coexistence of different cell types in some organs, cancers can be
further classified as carcinoma (epithelial cells), sarcoma (connective tissue),
myeloma (plasma cells), leukemia (bone marrow), and lymphoma (cells of the
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lymph system), blastoma (precursor cells) etc. If we take kidney cancer as an
example, there are renal cell carcinoma, transitional cell carcinoma, nephroblas-
tomas, and renal sarcoma. The renal cell carcinoma (RCC) is the most common
kidney cancer, contributing to 90 percent of the cases, and it can be classified
into a few subgroups (clear cell RCC, Papillary RCC, Chromophobe RCC, duct
RCC and others) according to the phenotype of cancer cells[12, 13]. Indeed, it is
quite astonishing that there are more than 100 different types of cancer known
at present (see the full cancer list in https : //www.cancer.gov/types#k)[1, 14],
which explains the difficulty in determining broad principles that drive the ori-
gin and evolution of these diseases. Yes, we are facing not a single disease but
hundreds of them. Although all of these diseases share some similar hallmarks
as summarized in the landmark reviews[1, 15], there appears to be no universal
treatment (nor will there be in the near future) for these diseases due to the
lack of understanding of the underlying mechanisms of cancer evolution.
2.2 Evolution of cancer
In addition to the many faces of cancer that appear in different organs, another
challenge for cancer treatment comes from tumor evolution. As proposed by
Nowell in 1976, cancer is now widely viewed as a clonal evolutionary process[6,
11]. Due to the imperfect genome replication process, environment exposures
and heredity, a normal cell can transform into a cancer cell by acquiring genetic
mutations, which occur on the time scale of a few decades[16, 11]. During cancer
progression, tumor cells constantly face the selective pressures derived from their
complex microenvironment, such as competition from the surrounding healthy
cells for nutrients and space for growth[17]. In addition, hypoxia, pH change,
immune surveillance and other potential factors all threaten the survival and
growth of tumor cells[18, 19, 20]. Therefore, tumor cells generate new traits
through continuous evolution, which is just one of the major reasons for the
failure of chemotherapy, radiotherapy and other widely applied methods used
to treat cancer patients[6, 11].
We have gained considerable knowledge from studies of tumor evolution
through animal models[21, 22]. The advent of many modern techniques, such
as next generation sequencing have helped us get a deeper understanding for
the genetic basis of cancer[23]. However, it is still very difficult to study tumor
evolution in humans due to the inaccessibility of tumor biopsies from patients
at different time points. Instead, the tumor evolutionary history obtained in
most studies are derived from patient samples at a single time point based on
assumptions, which are frequently violated as the tumor evolves[24]. Hence,
a clear and complete picture about tumor evolution has not emerged. Many
models have been proposed to describe the tumor evolution process, such as the
linear sequential model, branched, neutral and punctuated evolution of tumors
(see Fig. 1)[24, 25]. One common feature in all these models is that different
subpopulations could appear and coexist in a tumor, which is the cause of
pervasive cancer heterogeneity.
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2.3 Cancer heterogeneities
Cancer is driven by accumulation of genetic mutations especially the “driver
mutations”, which convey selective advantage to cancer cells. With the advent of
sequencing technology, genome-wide association studies (GWAS) is affordable,
thus giving us a powerful tool to search for cancer driver genes. The list of
cancer driver genes is continuously growing and the number has reached around
300 recently[26, 27]. A few cancer genes such as TP53 appear in many cancers
while each cancer type usually has its own specific driver mutations. Therefore,
different cancer patients have distinct tumor evolutionary processes, which leads
to the interpatient heterogeneity (see Fig. 2)[7, 8]. Personalized cancer medicine
has been proposed, and is necessary due to this type of heterogeneity[28].
As the cancer cells escape the primary site and seed other sites of the body,
they finish the transition into the last and fatal stage, referred to as cancer
metastasis - responsible for 90% of cancer patient death[29]. Whether new driver
mutations are required for the cancer metastasis is unresolved[30, 31, 32, 33].
However, distinct new mutations can appear both at the primary and metastatic
sites after the spatial isolation is established among cells at different sites[34].
It leads to the next level of heterogeneity, intrapatient heterogeneity which is
one of the reasons for cancer recurrence after treatment (see Fig. 2).
In addition to the two types of cancer heterogeneities described above, the
intratumor heterogeneity (ITH, see Fig. 2), which refers to the coexistence of
different subpopulations in a single tumor has been found in many cancers[9,
35, 36, 37, 38, 39, 40, 41]. ITH plays a crucial role in almost all stages of
cancer such as tumor progression, metastasis, drug resistance and recurrence
of cancer[42, 43, 44]. Therefore, understanding the ITH is a major step in
investigating cancer heterogeneity because it can help design better therapy to
avoid drug resistance and cancer recurrence.
The evolutionary models mentioned above all point to the possibility that
different subpopulations (with distinct mutations) can coexist in a single tumor.
In these models, the subpopulations interact with each other mainly through
cell competition irrespective of the selective action under linear and branched
models or the drift effect in neutral and punctuated models. However, increasing
experimental evidence found that the cooperation among distinct cell subpop-
ulations in a tumor is essential for tumor maintenance [45], enhanced tumor
growth [46], and even cancer metastasis [44, 47, 48]. Surprisingly, a minor sub-
population is sufficient to support the whole tumor growth and determine the
clinical course [49, 50, 51]. Hence, the different types of cell-cell interactions
have to be considered to better understand the mechanisms of ITH, which is
often neglected in many theoretical models. The lack of understanding of ITH
greatly impairs the progress of developing more effective therapies for cancer
patients.
4
3 Mathematical models of ITH
3.1 The multistage model of cancer evolution
In the past few decades, many innovative mathematical models have been pro-
posed to study the cancer evolutionary process, including cancer initiation, pro-
gression, and metastases[52]. A simple multistage model that cancer is driven by
a number of driver mutation events was proposed to explain the age-dependent
cancer incidence rate more than sixty years ago[53]. The Moran process ac-
counts for the cell division, apoptosis, and mutation process in tumor evolution
for a fixed cell population size. It has been widely used to investigate the ac-
cumulation of mutations and cancer initiation[54, 55, 56, 57, 58]. Other models
which further include the spatial structure of tumors and its related microen-
vironment such as the oxygen and nutrient concentrations are considered to
investigate the growth dynamics of tumor by using partial differential equations
or an agent-based model[59, 60, 61, 62, 63].
3.2 ITH under competition and cooperation
Evolutionary models have also been used to study ITH[64, 65, 66, 67], and
many insightful results have been obtained from these studies, such as the ex-
tent of ITH and factors influencing ITH. There are two crucial assumptions in
these theoretical studies. The genetic mutations only confer fitness advantage
to the cell itself (cell-autonomous effect), and tumor cells interact with each
other through competition. However, there is increasing evidence that tumors
cannot overcome the microenvironmental constraints only through autonomous
increase of the cell growth rate[68, 69, 70, 71]. In contrast, enhancement of
survival and proliferation rates through non-cell-autonomous effects by factors
such as metalloproteinases and cytokines are critical for tumor progression[72].
Therefore, these factors secreted by certain tumor/normal cells (‘producer’) can
bring cooperation among different cell subpopulations instead of competition.
Such a cooperation can in principle accelerate tumor progression. Instead of one
population accumulating all the mutations required for cancer development[15],
a few partially transformed subpopulations with each containing one or two
mutations can realize this procedure through their cooperation[10, 73].
3.3 Evolutionary game theory
The evolutionary game theory (EGT) provides a novel and unique avenue for
investigating ITH accounting for the interactions among subpopulaitons of tu-
mor or between cancer and normal cells[74, 75, 76, 77, 78, 79]. The EGT is a
subfield of game theory (GT), which provides mathematical models for study-
ing the strategic interaction among individuals[80, 81]. An individual (‘player’)
receives a payoff during the game depending on both the player and also the be-
havior (‘strategy’) of others. For EGT in cancer research, the players are cancer
or normal cells, and the payoff is their fitness while the strategies are pheno-
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types adopted by players[77]. The advantage of EGT is that it can describe the
time-dependent evolution of the relative abundance of each cell type, determine
the equilibrium conditions and the stability of phenotype coexist[52]. Here, we
briefly describe the EGT. The evolutionary games for two cells of different types
A, and B are frequently represented by the pay-off matrix,
A B
A WAA WAB
B WBA WBB
where WIJ(I, J ≡ A,B) represents the fitness of the cell type I interacting with
the cell type J . The cell-cell interaction can be direct or indirect and its effect
can also be competition or cooperation due to the influences of space, nutrients,
information, growth factors and other microenvironmental factors[17, 77, 82].
Therefore, the fitness function WIJ of the cells can also be expressed by very
different mathematical formula[77]. As the two different cell populations, in-
stead of just two cells, are well-mixed with each other[82], the average fitness
(wA, wB) of the two cell types may be described as,
wA = fAWAA + (1− fA)WAB , (1)
wB = fBWBA + (1− fB)WBB , (2)
where fA, and fB are the fractions of the cell type A, and B in the population,
respectively. From the fitness functions of the cells, the time-(in)dependent
properties of the cell population as mentioned above can be calculated.
In a few latest studies[83, 84], the EGT has been adopted to explain ITH
in pancreatic cancer starting from the simplest case with only two different
types of cancer cells. One cell type can produce a growth factor while the other
does not. The growth factor (often called “public goods”) can be consumed
by both cell types and promote their proliferation. Qualitative conclusions are
obtained for the coexistence of two cell subpopulations which are consistent with
experimental observations.
4 Public goods game
In a recent study[76], we investigated the ITH through the “public goods game”
among cancer cells quantitatively. Instead of assuming a constant population
size, and ideal fitness functions, we consider a growing cell population, and took
cell growth rate as the fitness function. Both these quantities can be measured
from experiments directly. In the following, we will briefly introduce the model
and discuss some of the most important results that we discovered.
The public goods game is an economic model, which has extensive applica-
tions in many areas, such as microbial colonies, and insect communities, and
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even cancer research [85, 86, 87, 88, 89, 90, 77]. There are two players in this
model based on whether they produce the public goods (called ‘producer’) or
not (‘non-producer’). Both of them derive benefits from the public goods while
the producer usually has to pay a cost for the public goods production. We
investigate the underlying mechanism of ITH during cancer progression within
the framework of public goods game. We will give two examples to show how
cooperation among cancer cell subpopulations can lead to the establishment of
a stable ITH, which could be applicable to many other cancers.
4.1 Models
We consider two types of cancer cells with one of them producing a public
good (see Fig. 3). In the insightful in vitro experiment[83], the public good is
the insulin-like growth factor II (IGF-II). First, we focus on this experiment
and then we apply the same idea to describe the ITH observed in an in vivo
experiment on glioblastoma multiforme[91]. In the first experiment, both cell
types are taken from cancer cells of mice with insulinomas (a type of pancreatic
cancer). One cell type can produce IGF-II (the producer (+/+)) while the non-
producer (-/-) cells have IGF-II gene deleted, which means they can no longer
produce IGF-II but can still consume it from the environment.
One critical element in using the concept of the public goods game is how
to define the payoff function. Often a rather complex, frequency dependent
function is assigned to both players[86, 83]. Here, we use the growth rate as the
fitness functions for both the cell types as they can be measured in experiments
directly. A non-linear growth function[83] is found for the growth rate (w−)
of the non-producer cells as a function of IGF-II concentration (c), which is
well-described by the Hill-like function,
w− = a1 + λ1cα/(aα2 + c
α) . (3)
where a1 = 2.0, λ1 = 18.9, α = 0.7, and a2 = 3.2[76]. Although it has not been
measured, we expect that the producer cells also have a similar functional form
as Eq. (3) for their fitness (w+), which leads to,
w+ = g(c)− p0 , (4)
where g(c) is the same Hill-like function as in Eq. (3), and p0 is the cost paid
by producer cells due to the IGF-II production. The IGF-II concentration (c)
has two sources once two cell types are mixed with each other. One is from
the production of the producer cells, and the other is supplied exogenously (in
the culture medium). The IGF-II produced by the producer will depend on
the fraction f+ in the population. Therefore, the IGF-II concentration (c+)
available for the producer can be written as,
c+ = af+ + c0 , (5)
where a is the coefficient for the allocation of IGF-II produced by +/+ cells,
and c0 represents the exogenous supply of IGF-II. Similarly, the available IGF-II
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(c−) for the non-producer is given by,
c− = bf+ + c0 , (6)
The parameter b is the coefficient of allocation of IGF-II produced by +/+ cells.
We use different parameters a, b to indicate that the producer and non-producer
can get different fraction of IGF-II that are produced by the former cells.
The evolution of the fraction f+ (f−) of producers (non-producers) can be
derived from the replicator equations,
∂f+
∂t
= (w+ − 〈w〉)f+ , (7)
and,
∂f−
∂t
= (w− − 〈w〉)f− , (8)
where the average fitness 〈w〉 is,
〈w〉 = w+f+ + w−f− , (9)
with f+ + f− = 1 being the normalization condition. Let the number of pro-
ducers and non-producers be N+, and N−, respectively. The whole population
size, N , is the sum of N+ and N−. The system size, N , is a time dependent
quantity, which is often neglected in other models for simplicity [83, 92]. Here,
we describe the time-dependent changes in the system size, N , through
∂N
∂t
= w+N+ + w−N− = 〈w〉N . (10)
Then, we can study the conditions for the coexistence of producers and non-
producers from the equations above.
4.2 Unequal allocation of public goods results in stable
ITH
The first important result derived using our model is that the emergence of a
stable ITH requires an unequal allocation of public goods between producer and
non-producer cells. The allocation of the public goods produced by the produc-
ers is determined by the ratio, b/a, in Eqs. (5) and (6). A unity for the value of
b/a means that the two cell types share the public goods equally. Therefore, the
two cell types will have the same fitness function, expect a constant shift p0 due
to the cost paid by the producer (see Eqs. (3) and (4) and the Fig. 4A). There
is only one stable state under this condition (see the filled blue dot in Figs. 4A
and D), a homogeneous state consisted of only non-producer would be expected
as long as the initial fraction f+(0) < 1. On the other hand, given b/a = 0
which means producers do not share any public good with the non-producer.
Then, the fitness of the non-producer does not depend on the fraction of the
producer any more. There is a heterogeneous state but it is unstable under this
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condition (see the open circle in Fig. 4A and the evolution of f+ in Fig. 4E).
However, we find a stable heterogeneous state if 0 < b/a < 1 (see the filled blue
dots in Fig. 4C and F), which indicates that the producer maintains a higher
fraction of the public goods produced. There is a negative feedback mechanism
close to this stable coexisting state, which can be observed from Fig. 4C.
To validate our conclusion that it is the unequal allocation of public goods
leading to the establishment of a stable coexist state, we calculated the the inter-
nal equilibrium fractions (0 < f i+ < 1) of +/+ cells at different concentrations
of serum (c0) which has been detected in experiments. The +/+ cell fraction
is measured after 5 days co-culture of +/+ and -/- cells under eleven different
initial fractions of cells (with f+(t = 0) almost evenly distributed between 0
and 1) and different amounts of serum[83]. There are three free parameters
in our model, a, b, and p0. From the equal fitness (≈ 14.4) of producer and
non-producer cells and the +/+ cell fraction approaching 1 at the stable in-
ternal state under c0 = 0 observed in the experiments[83], the parameter b ≈
8 is obtained from Eqs. (3) and (6). Similarly, we can derive the values of a
and p0 based on the experimental results of internal equilibrium states. We find
that our theoretical model captures the experimental observations very well (see
the upper panel in Fig. 5). No quantitative explanations have been reached for
similar experiments from other models at present. Interestingly, the ratio of
b/a obtained through the comparison between our theoretical results and ex-
periments is 0.1 which is just located at the interval we proposed above for the
formation of a stable ITH (see the low panel of Fig. 5 for the illustration of one
stable ITH state).
4.3 Cost p0 influence cell cooperation
Another important result is that the cost p0 paid by producers has a strong
influence on cell cooperation. As the fitness of producers is reduced by p0 due
to the production of the public goods, we investigate whether this parameter
has any influence on the cooperation of different subpopulations. From the di-
agram of the internal equilibrium fraction f i+ of the producer as a function of
the exogenous resource level at varied values of p0 (see Fig. 6), we found a crit-
ical concentration for exogenous resources above which there is only one stable
homogeneous state consisted of non-producers. And this critical concentration
increases as the value of p0 decreases. A second critical value (see the star sym-
bols in Fig. 6A) is observed for exogenous resources as p0 takes small values.
There is no stable heterogeneous states after the exogenous resource level is
lower than this critical value.
To better understand the influence of p0 on cell cooperation, we calculated
a phase diagram in terms of the initial fraction f+(0) and percentage of serum
(see Figs. 6B and 6C). There are three distinct phases represented in different
colors (pink, blue, and purple). Two stable homogeneous states consist of either
producers (pink region) or non-producers (blue region). The third phase corre-
sponds to a stable heterogeneous state consisted of both subpopulations (purple
region). The area of the three regions is strongly influenced by the value of p0
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(see Figs. 6B and 6C). A heterogeneous phase is established at modest levels of
exogenous resources and higher f+(0). We also find that a higher cost paid by
the producers actually helps the establishment of a heterogeneous system (see
the change of the purple region in Figs. 6B and 6C).
4.4 Cooperation among cancer subpopulations in Glioblas-
toma multiforme
Cooperation among different cell types has been found in several types of can-
cer such as breast cancer[45], prostate cancer[93] and Glioblastoma multiforme
(GBM)[91]. Here, we take GBM, which is the most aggressive and fatal brain
cancer [94] as an example, to show how the same model based on public goods
explains equally well the mechanism of ITH in GBM. Two types of cancer cells
are frequently found in GBM with different expressions of epidermal growth fac-
tor receptor (EGFR) [95]. Apparently, the coexistence of the two cell types in
GBM promotes the cancer progression and leads to a worse prognosis of the pa-
tients [96, 97]. Several studies found that the GBM cells with rearrangement of
EGFR gene (∆ cells) can secrete factors (Interleukin-6 and Leukemia inhibitory
factor) to enhance cell proliferation and inhibit its apoptosis [91, 98].
A recent study investigated the interactions between GBM cells with ampli-
fied levels of EGFR (referred to as WT cells) and ∆ cells systematically[91]. A
fixed amount of cancer cells (2× 105 cells) with different initial fractions of the
two cell types are injected into athymic nude mice (4 to 5 weeks old). Then, the
size of the established tumors was measured at different times (see the different
symbols in Fig. 7). It is difficult for the WT cells alone to induce a new tumor
in the mice (see the pink upside down-triangles in Fig. 7) while a tumor can
be quickly generated by the ∆ cell alone (see the the blue squares in Fig. 7).
Meanwhile, a faster tumor growth rate is found as the initial fraction of ∆ cells
increases until it reaches 90% (see the inset of Fig. 7). However, the maximum
growth rate is found at the mixture of 10% WT and 90% ∆ cells but not 100%
∆ cells which seems to indicate a cooperative relation between these two cell
types.
We applied the public goods model to explain the non-trivial experimental
observations summarized above. The WT and ∆ cells are considered to be the
non-producer and producer, respectively. The IL-6 and/or LIF secreted by ∆
cells is the public goods. We used a simple fitness function (w−) for the WT
cell as above which is given by,
w− = bf+/(1 + bf+) . (11)
The fitness function (w+) for ∆ cells is,
w+ = af+/(1 + af+)− p0 . (12)
The different parameters a and b indicate that the public goods (produced by
the ∆ cells) can be shared unequally between the two cell types. There are only
three free parameters in our model, which can be calculated in the following
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way. The average fitness of the population is given by 〈w〉 = w+ as it contains
only producer cells with f+ = 1 (see Eq. (9)). Therefore, the population size,
N , can be calculated from Eq. (10) which increases exponentially, N = N0e
w+t.
From the growth curve (see the blue square in the upper panel of Fig. 6) of the
∆ cells measured in experiments, we obtain,
a
1 + a
− p0 ≈ 0.335 , (13)
where 0.335 is obtained from the exponential fit. It is found that the two types
of cells grow at the same rate given f+ = f−[91], which leads to,
0.5a
1 + 0.5a
− p0 = 0.5b
1 + 0.5b
. (14)
In addition, the evolution of N(t) can be described by N(t) = N0e
w−t given
f+ = f−, and w+ = w− as the average fitness 〈w〉 = 0.5(w+ +w−) = w−. Thus,
we obtain the following expression,
0.5b
1 + 0.5b
≈ 0.321 , (15)
from the tumor growth curve (orange dots) in the upper panel of Fig. 7. The
constant 0.321 is obtained from the exponential fit (see the orange dotted line
in Fig. 7). Therefore, the three parameters in our model can be derived using
Eqs. (13)-(15), which leads to, a = 68.4, b = 0.946, and p0 = 0.651.
To test our model, we predicted the tumor growth behavior at 10%, and 90%
of ∆ cells, and found that our predictions agree very well with experimental
observations (see the lower panel of Fig. 7). We also calculated the tumor
growth rate as a function of the fraction of ∆ cells[76] and found that there is
a maximum tumor growth rate at an intermediate value (≈0.77) of the ∆ cells
fraction which is consistent with experimental observations and can be test in
future experiments.
Our theory also provides some hints for the frequent observations of both WT
cells and ∆ cells in GBM patient and its poor prognosis. From the evolution of
the fraction of ∆ cells under different initial conditions (Fig. 8A), we found that
the heterogeneous state is stable even f+(0) varies from 0.1 to 0.9. Therefore,
a quick recurrence of GBM is possible if some ∆ cells still exist in the tumor.
Cooperation between different cancer types greatly enhanced their survival and
progression. Hence, new drugs and methods should be developed to eliminate
such a relation. Our theory predicts that a rich culture medium can encourage
cell competition instead of cooperation, which might provide potential treatment
strategies for GBM and other similar cancer types (see Fig. 8B).
5 Discussion
In this article, we briefly reviewed different aspects of cancer complexity from
the surprisingly long list of cancers. How to deal with such a complex evolving
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system poses a big challenge for biologists, clinicians and presents new opportu-
nities for physicists. The ten hallmarks of cancer summarized by Hanahan and
Weinberg in 2011 provide a guideline for understanding the progression of neo-
plastic disease[15]. Due to the ubiquitous heterogeneity present in cancer, there
is no universal treatment method for all cancers although the latest immunother-
apy brings great hope in this direction[99, 100]. A deeper understanding for the
cancer evolution and the heterogeneity at all levels is a potentially reachable
goal that would enable control or even devise effective treatment of the fatal
disease in the future. One of the obstacles slowing down progress comes from
the complex interactions among cancer cells, which leads to the formation of a
complex cancer cell society, and to the emergence of unexpected phenomena[10].
This could serve as a platform for physicists to give detailed and quantitative
understandings of the underlying mechanisms of complex systems using mathe-
matical models. We have provided just one example to illustrate the possibility
of applying physical models in studying important questions in cancer research.
It is quite encouraging that a simple physical model provides a unified descrip-
tion of different phenomena in pancreatic cancer and GBM in a quantitative
manner. In addition, the model can also be used to explain the origin and
maintenance of ITH in other cancers in which similar cell-cell interactions are
present[45, 93]. These ideas could be useful in microbial colonies, insect commu-
nities, human society, and other systems [101, 102, 103]. We expect that similar
physical models and ideas from very different fields[52, 104] could help us better
understand the disease, and might also provide new ideas and methods for more
efficacious cancer therapy.
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Figure 1: Four tumor evolution models. (A) Linear evolution: Cells
accumulate driver mutations (with selective advantage for the cancer cells) se-
quentially during which selective sweeps occur. (B) Branching evolution: New
mutations appear before selective sweeps are completed and divergent subclones
emerge from the same ancestor. (C) Neutral evolution: Only passenger muta-
tions (without any selective advantage) accumulate stochastically in tumor cells.
(D) Punctuated evolution: Most of the detectable subclonal mutations occur in
short bursts of time at early stages of cancer evolution. Different colors represent
subclones with different mutations.
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Figure 2: Cancer heterogeneity. Three levels of cancer heterogeneity: in-
terpatient, intrapatient, and intratumor heterogeneity. Different color dots rep-
resent varied tumors or tumor cells with different genetic mutations.
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Producer Non-Producer
Public goods
Figure 3: Schematic figure for the public goods game of two cell
types. The producers (cyan cells) generate public goods (small green dots)
which are shared among producer and non-producer cells (magenta cells). The
public goods promote the proliferation of both cell types. The inset rectangle:
A detailed picture shows the circuit of public goods production and the feedback
for the proliferation of producer and non-producer.
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Figure 4: (A)-(C): The growth rates of producer (+/+) and non-producer
(-/-) cells as a function of the +/+ cell fraction (f+) at different allocation
strategies of IGF-II generated by the +/+ cells. (A) The IGF-II are shared
equally between two cell types (b = a = 8), (B) +/+ cells do not share any
IGF-II with -/- cells (b = 0, and a = 8), (C) +/+ cells only share a small
fraction of IGF-II with -/- cells (b = 8, and a = 80). The parameter value
c0 = 1 and p0 = 4.65. The growth rate of +/+ (-/-) cells are shown in solid red
(dash-dotted blue) lines. The stable or unstable fixed points are represented by
filled or empty circles, respectively. (D)-(F): The fraction f+(t) of +/+ cells
as a function of time at different initial conditions corresponding to the figures
(A)-(C) on the left, accordingly. The growth rate is derived from the cell’s
relative density change at the log phase [83]. The time unit is in days. Figure
is adopted from Ref. [76].
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t (days)
Figure 5: Upper panel: The producer fraction f i+,( i ≡ s or us, with s for stable
and us for unstable state) at internal equilibrium states (observed on day 5 under
different initial fractions of f+(t = 0) in experiments) as a function the levels
of serum. The red squares (blue circles) represent stable (unstable) states. The
error bars indicate the upper and lower boundaries observed in experiments.
Our theoretical predictions are illustrated by the solid lines. The parameter
values: a = 80, and p0 = 4.65. Lower panel: The time dependence of f+(t) (the
fraction of +/+ cells) at 3% of serum under various initial conditions. The inset
is a zoom in for f+(t) with f+(0) = 0.05. Figure is adopted from Ref. [76].
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Figure 6: (A) The producer fraction f i+, (i ≡ s, us) at internal equilibrium
states as a function of the serum level at different values of p0. The red (blue)
lines indicate stable (unstable) equilibrium fractions f+. Arrows and purple
stars indicate the two critical serum concentrations. (B) and (C) Phase diagrams
in terms of the initial fraction f+(0) and % of serum. The values of p0 in (B)
and (C) are 4.65 and 4.00, respectively. There are three stable phases in these
two figures. (i) A homogeneous phase with producers only (see the region in
pink color). (ii) A heterogeneous phase with both producers and non-producers
(purple color). The red dashed line indicates the stable equilibrium fraction of
producers. (iii) A homogeneous phase with non-producers only (see the blue
color). The red and blue spheres labeled by +/+ and -/- represent the producer
and non-producer cells, respectively. Figure is adopted from Ref. [76].
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Figure 7: The evolution of the tumor volume. The GBM tumor volume
as a function of time at different initial fractions of WT and ∆ cells. The
experimental data are represented by symbols. The data from the upper panel
are used to obtain the three free parameter values (a = 68.4, b = 0.946 and
p0 = 0.651) in the model. The purple and green curves at the lower panel are
theoretical predictions. Error bars indicate the standard error. The inset gives
the complete experimental data. Figure is adopted from Ref. [76].
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Figure 8: Prediction of the fraction f+(t) of ∆ cells as a function of time under
distinct initial conditions (f+(t = 0)) in GBM. (A) Without external supply of
public goods (c0 = 0.0); (B) With external supply of public goods, and the total
public goods becomes af+ + c0 (bf+ + c0) for the producer (non-producer) with
c0 = 1.0. Other parameters are the same as in Fig. 7. The labels in (A) and
(B) are the same. Figure is adopted from Ref. [76].
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Table 1: Cancer types, estimated number of new cancer cases and deaths in
United States, 2019[2].
Estimated New Cases Estimated Deaths
All sites 1,762,450 606,880
Tongue 17,060 3,020
Mouth 14,310 2,740
Pharynx 17,870 3,450
Other oral cavity 3,760 1,650
Esophagus 17,650 16,080
Stomach 27,510 11,140
Small intestine 10,590 1,590
Colon 101,420 51,020
Rectum 44,180
Anus, anal canal, and anorectum 8,300 1,280
Liver and intrahepatic bile duct 42,030 31,780
Gallbladder and other biliary 12,360 3,960
Pancreas 56,770 45,750
Other digestive organs 7,220 2,860
Larynx 12,410 3,760
Lung and bronchus 228,150 142,670
Other respiratory organs 5,880 1,080
Bones and joints 3,500 1,660
Soft tissue (including heart) 12,750 5,270
Skin (excluding basal and squamous) 104,350 11,650
Breast 271,270 42,260
Uterine cervix 13,170 4,250
Uterine corpus 61,880 12,160
Ovary 22,530 13,980
Vulva 6,070 1,280
Vagina and other genital, female 5,350 1,430
Prostate 174,650 31,620
Testis 9,560 410
Penis and other genital, male 2,080 410
Urinary bladder 80,470 17,670
Kidney and renal pelvis 73,820 14,770
Ureter and other urinary organs 3,930 980
Eye and orbit 3,360 370
Brain and other nervous system 23,820 17,760
Endocrine system 54,740 3,210
blood cancer 176,200 56,770
Other and unspecified primary sites 31,480 45,140
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